Prognostic molecular markers in cancer - quo vadis?

Histopathology

Volumn 63, Issue 3, 2013, Pages 297-308

  Søland, Tine M ^a   Brusevold, Ingvild J ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Immunohistochemistry; Molecular marker; Oral cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CELL HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDLINE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TISSUE MICROARRAY;

IMMUNOHISTOCHEMISTRY; MOLECULAR MARKER; ORAL CANCER; PROGNOSIS;

CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MOUTH NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84882703979     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12184     Document Type: Review

References (82)

1. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2005; 2; 416-422.
2. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br. J. Cancer 2010; 102; 173-180.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J. Clinicians 2011; 61; 69-69.
4. Harmer M. TNM classification of malignant tumours, 3rd edn. Geneva: International Union Against Cancer, 1987.
5. Barnes LE, Eveson JW, Reichart P, Sidranski D. World Health Organization classification of tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press, 2005.
6. Woolgar JA. Pathology of the n0 neck. Br. J. Oral Maxillofac. Surg. 1999; 37; 205-209.
7. Bryne M, Boysen M, Alfsen CG et al. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res. 1998; 18; 4757-4764.
8. Bryne M, Koppang HS, Lilleng R, Kjaerheim A. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J. Pathol. 1992; 166; 375-381.
9. Klimowicz AC, Bose P, Nakoneshny SC et al. Basal ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. Eur. J. Cancer 2012; 48; 2166-2174.
10. Bose P, Klimowicz AC, Kornaga E et al. Bax expression measured by aquanalysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer 2012; 12; 332.
11. Kyzas PA, Denaxa-Kyza D, Ioannidis JP. Almost all articles on cancer prognostic markers report statistically significant results. Eur. J. Cancer 2007; 43; 2559-2579.
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100; 57-7.
13. Ahmed MM. Expression profile of apoptotic mediators and proliferative markers in oral squamous cell carcinoma. J. Egypt. Natl Canc. Inst. 2009; 21; 85-92.
14. Andressakis D, Lazaris AC, Tsiambas E, Kavantzas N, Rapidis A, Patsouris E. Evaluation of caspase-3 and caspase-8 deregulation in tongue squamous cell carcinoma, based on immunohistochemistry and computerised image analysis. J. Laryngol. Otol. 2008; 122; 1213-1218.
15. Camisasca DR, Honorato J, Bernardo V et al. Expression of bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol. 2009; 45; 225-233.
16. Costa NL, Alencar Rde C, Valadares MC, Silva TA, Mendonca EF, Batista AC. The clinicopathological significance of the expression of granzyme B in oral squamous cell carcinoma. Oral Oncol. 2010; 46; 185-189.
17. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Expression of bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 2010; 57; 304-316.
18. Hayry V, Makinen LK, Atula T et al. Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br. J. Cancer 2010; 102; 892-897.
19. Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J. Oral Pathol. Med. 2008; 37; 364-371.
20. Li J, Huang H, Sun L et al. Mir-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 2009; 15; 3998-4008.
21. Diniz-Freitas M, Garcia-Caballero T, Antunez-Lopez J, Gandara-Rey JM, Garcia-Garcia A. Pharmacodiagnostic evaluation of EGFR expression in oral squamous cell carcinoma. Oral Dis. 2007; 13; 285-290.
22. Freudlsperger C, Rohleder SE, Reinert S, Hoffmann J. Predictive value of high Ki-67 expression in stage I oral squamous cell carcinoma specimens after primary surgery. Head Neck 2011; 33; 668-672.
23. Gonzalez-Moles MA, Ruiz-Avila I, Gil-Montoya JA, Esteban F, Bravo M. Analysis of Ki-67 expression in oral squamous cell carcinoma: why Ki-67 is not a prognostic indicator. Oral Oncol. 2010; 46; 525-530.
24. Kim YH, Kim SM, Kim YK, Hong SP, Kim MJ, Myoung H. Evaluation of survivin as a prognostic marker in oral squamous cell carcinoma. J. Oral Pathol. Med. 2010; 39; 368-375.
25. Kok SH, Chang HH, Tsai JY et al. Expression of cyr61 (ccn1) in human oral squamous cell carcinoma: an independent marker for poor prognosis. Head Neck 2010; 32; 1665-1673.
26. Madan R, Brandwein-Gensler M, Schlecht NF et al. Differential tissue and subcellular expression of erm proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck 2006; 28; 1018-1027.
27. Moergel M, Abt E, Stockinger M, Kunkel M. Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol. 2010; 46; 667-671.
28. Pukkila M, Kosunen A, Ropponen K et al. High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J. Clin. Pathol. 2007; 60; 267-272.
29. Sawhney M, Matta A, Macha MA et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int. J. Cancer 2009; 124; 2098-2105.
30. Su L, Wang Y, Xiao M, Lin Y, Yu L. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2010; 110; 484-491.
31. Tanji Y, Osaki M, Nagahama Y, Kodani I, Ryoke K, Ito H. Runt-related transcription factor 3 expression in human oral squamous cell carcinomas; implication for tumor progression and prognosis. Oral Oncol. 2007; 43; 88-94.
32. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of MCM2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. Br. J. Cancer 2009; 100; 1128-1134.
33. Shao Z, Zhang WF, Chen XM, Shang ZJ. Expression of EPHA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol. 2008; 44; 1110-1117.
34. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. Hif1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005; 5; 84.
35. Brennan PA, Dennis S, Poller D, Quintero M, Puxeddu R, Thomas GJ. Inducible nitric oxide synthase: correlation with extracapsular spread and enhancement of tumor cell invasion in head and neck squamous cell carcinoma. Head Neck 2008; 30; 208-214.
36. Chen CH, Chien CY, Huang CC et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 2009; 28; 2723-2737.
37. Gasparoni A, Della Casa M, Milillo L et al. Prognostic value of differential expression of laminin-5 gamma2 in oral squamous cell carcinomas: correlation with survival. Oncol. Rep. 2007; 18; 793-800.
38. Marioni G, Gaio E, Giacomelli L et al. Maspin subcellular localization and expression in oral cavity squamous cell carcinoma. Eur. Arch. Otorhinolaryngol. 2008; 265(Suppl. 1); S97-S104.
39. Mitra RS, Goto M, Lee JS et al. Rap1gap promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low n-stage squamous cell carcinoma. Cancer Res. 2008; 68; 3959-3969.
40. Park SY, Lee SA, Han IH et al. Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma. Oncol. Rep. 2007; 17; 81-87.
41. Reis PP, Tomenson M, Cervigne NK et al. Programmed cell death 4 loss increases tumor cell invasion and is regulated by MIR-21 in oral squamous cell carcinoma. Mol. Cancer 2010; 9; 238.
42. Sasahira T, Kirita T, Bhawal UK et al. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology 2007; 51; 166-172.
43. Silva SD, Perez DE, Nishimoto IN et al. Fatty acid synthase expression in squamous cell carcinoma of the tongue: clinicopathological findings. Oral Dis. 2008; 14; 376-382.
44. Siriwardena BS, Kudo Y, Ogawa I, Udagama MN, Tilakaratne WM, Takata T. VEGF-C is associated with lymphatic status and invasion in oral cancer. J. Clin. Pathol. 2008; 61; 103-108.
45. Theocharis S, Klijanienko J, Giaginis C et al. Expression of DNA repair proteins, MSH2, MLH1 and MGMT in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients' survival. J. Oral Pathol. Med. 2011; 40; 218-226.
46. Wang YF, Chen JY, Chang SY et al. Nm23-h1 expression of metastatic tumors in the lymph nodes is a prognostic indicator of oral squamous cell carcinoma. Int. J. Cancer 2008; 122; 377-386.
47. Zhao D, Pan J, Li XQ, Wang XY, Tang C, Xuan M. Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance. J. Oral Pathol. Med. 2008; 37; 616-625.
48. Soland TM, Husvik C, Koppang HS et al. A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas. J. Oral Pathol. Med. 2008; 37; 535-542.
49. Ryott M, Marklund L, Wangsa D, Elmberger G, Munck-Wikland E. Cyclooxygenase-2 expression in oral tongue squamous cell carcinoma. J. Oral Pathol. Med. 2011; 40; 385-389.
50. Ayala FR, Rocha RM, Carvalho KC et al. Glut1 and glut3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 2010; 15; 2374-2387.
51. Kunkel M, Moergel M, Stockinger M et al. Overexpression of glut-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007; 43; 796-803.
52. Macha MA, Matta A, Kaur J et al. Prognostic significance of nuclear PSTAT3 in oral cancer. Head Neck 2011; 33; 482-489.
53. Miller R. Technical immunohistochemistry: achieving reliability and reproducibility of immunostains. Society for Applied Immunohistochemistry 2001 annual meeting: ProPath Laboratory, Inc., 2001.
54. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer 2007; 14; 182-188.
55. Walker RA. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment I. Histopathology 2006; 49; 406-410.
56. Pozner-Moulis S, Cregger M, Camp RL, Rimm DL. Antibody validation by quantitative analysis of protein expression using expression of Met in breast cancer as a model. Lab. Invest. 2007; 87; 251-260.
57. Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 2006; 66; 7976-7982.
58. Rasmussen OF. Controls. In Kumar GR, Ludbeck R eds. Education guide. Immunohistochemical (IHC) staining methods. Carpinteria, CA: Dako, 2009; 127-130.
59. Sugiura T, Inoue Y, Matsuki R et al. VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: implications for use as a prognostic marker. Int. J. Oncol. 2009; 34; 673-680.
60. Soland TM, Brusevold IJ, Koppang HS, Schenck K, Bryne M. Nerve growth factor receptor (p75 Ntr) and pattern of invasion predict poor prognosis in oral squamous cell carcinoma. Histopathology 2008; 53; 62-72.
61. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat. Rev. Cancer 2011; 11; 9-22.
62. Kirkwood B, Sterne J. Essential medical statistics, 2nd edn. Chichester, UK: Wiley-Blackwell, 2003.
63. Souza LR, Fonseca-Silva T, Santos CC et al. Association of mast cell, eosinophil leucocyte and microvessel densities in actinic cheilitis and lip squamous cell carcinoma. Histopathology 2010; 57; 796-805.
64. de Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J. Oral Pathol. Med. 2007; 36; 191-197.
65. Oliveira LR, Ribeiro-Silva A, Costa JP, Simoes AL, Matteo MA, Zucoloto S. Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont. 2008; 106; 685-695.
66. Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic significance of p53 and p63 immunolocalisation in primary and matched lymph node metastasis in oral squamous cell carcinoma. Acta Histochem. 2007; 109; 388-396.
67. Szabo B, Nelhubel GA, Karpati A et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol. 2011; 47; 487-496.
68. Agra IM, Carvalho AL, Pinto CA et al. Biological markers and prognosis in recurrent oral cancer after salvage surgery. Arch. Otolaryngol. Head Neck Surg. 2008; 134; 743-749.
69. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br. J. Cancer 2009; 100; 1219-1229.
70. Lindstrom AK, Stendahl U, Tot T, Lidstrom BM, Hellberg D. Predicting the outcome of squamous cell carcinoma of the uterine cervix using combinations of individual tumor marker expressions. Anticancer Res. 2007; 27; 1609-1615.
71. Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. Hum. Pathol. 2010; 41; 1079-1086.
72. Motta Rda R, Zettler CG, Cambruzzi E, Jotz GP, Berni RB. Ki-67 and p53 correlation prognostic value in squamous cell carcinomas of the oral cavity and tongue. Braz. J. Otorhinolaryngol. 2009; 75; 544-549.
73. Shah NG, Trivedi TI, Tankshali RA et al. Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis. Head Neck 2009; 31; 1544-1556.
74. Fourati A, El May MV, Ben Abdallah M et al. Prognostic evaluation of p53, heat shock protein 70, Ki67, and CD34 expression in cancer of the tongue in tunisia. J. Otolaryngol. Head Neck Surg. 2009; 38; 191-196.
75. Won HS, Jung CK, Chun SH et al. Difference in expression of EGFR, PAKT, and PTEN between oropharyngeal and oral cavity squamous cell carcinoma. Oral Oncol. 2012; 48; 985-990.
76. Trivedi TI, Tankshali RA, Goswami JV, Shukla SN, Shah PM, Shah NG. Identification of site-specific prognostic biomarkers in patients with oral squamous cell carcinoma. Neoplasma 2011; 58; 217-226.
77. Vlatkovic N, El-Fert A, Devling T et al. Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck. Cancer 2011; 117; 2939-2950.
78. Chen SF, Yu FS, Chang YC, Fu E, Nieh S, Lin YS. Role of human papillomavirus infection in carcinogenesis of oral squamous cell carcinoma with evidences of prognostic association. J. Oral Pathol. Med. 2012; 41; 9-15.
79. Tamura T, Shomori K, Haruki T et al. Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. J. Oral Pathol. Med. 2010; 39; 328-334.
80. Lee JI, Jin BH, Kim MA, Yoon HJ, Hong SP, Hong SD. Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodont. 2009; 107; 678-684.
81. Bitu CC, Destro MF, Carrera M et al. Hoxa1 is overexpressed in oral squamous cell carcinomas and its expression is correlated with poor prognosis. BMC Cancer 2012; 12; 146.
82. Nakata Y, Uzawa N, Takahashi K et al. EGFR gene copy number alteration is a better prognostic indicator than protein overexpression in oral tongue squamous cell carcinomas. Eur. J. Cancer 2011; 47; 2364-2372.